

## PHORBOL ESTERS AND THYROLIBERIN HAVE DISTINCT ACTIONS REGARDING STIMULATION OF PROLACTIN SECRETION AND ACTIVATION OF ADENYLATE CYCLASE IN RAT PITUITARY TUMOUR CELLS (GH<sub>4</sub>C<sub>1</sub> CELLS)

JAN O. GORDELADZE,<sup>†</sup> TRINE BJØRO,<sup>‡</sup> BJØRN CHR. ØSTBERG,<sup>‡</sup> OLAV SAND,<sup>§</sup>  
PETER TORJESEN,<sup>‡</sup> EGIL HAUG<sup>‡</sup> and KAARE M. GAUTVIK<sup>\*</sup>

<sup>\*</sup>Institute of Medical Biochemistry and Institute for Surgical Research, <sup>§</sup>Institute of Biology, University of Oslo, P.Box 1112 Blindern, 0317 Oslo 3, and <sup>‡</sup>The Hormone Laboratory, Aker Sykehus, Oslo, Norway

(Received 27 July 1987; accepted 15 February 1988)

**Abstract**—The phorbol ester 12-O-tetradecanoyl phorbol 13-acetate (TPA) enhances the effects of TRH on phase II of prolactin secretion as well as on hormone synthesis at both low and high TPA receptor occupancy. Furthermore TPA, but not the biologically inactive substance 4 $\alpha$ -phorbol 12,13-didecanoate (4 $\alpha$ -PDD), stimulates the particulate bound adenylate cyclase with a time course paralleling that of TRH activation. However, the combined additions of TRH and TPA activate this cyclase in an additive manner while the Gpp(NH)p- and the forskolin-sensitive enzyme are unaffected by TPA addition. Polymyxin B, which inhibits protein kinase C, abolishes activation of adenylate cyclase by TPA without interfering with the stimulatory action of TRH. Also, when phosphatase activity is preferentially inhibited by pretreatment of the cells with sodium vanadate, the TRH-sensitive cyclase is unaltered, while TPA activation is obliterated. Maximal stimulation of adenylate cyclase by cholera toxin pretreatment, obliterated the actions of TRH and TPA. Cells pretreated with pertussis toxin retained their TRH-sensitive cyclase, however, TPA-responsiveness was lost.

We therefore suggest that the action of TPA as it relates to activation of adenylate cyclase, is probably mediated via the G<sub>i</sub> component of the adenylate cyclase complex, while TRH stimulates the enzyme via the classical pathway involving the stimulatory GTP binding protein (G<sub>s</sub>).

In the GH<sub>4</sub>C<sub>1</sub> rat pituitary cell line, which produces and spontaneously secretes prolactin, both thyroliberin (TRH) and the phorbol ester 12-O-tetradecanoyl phorbol 13-acetate (TPA) stimulate prolactin secretion and synthesis [1]. In these cells TRH, within seconds, elevates the cytosolic calcium concentration ([Ca<sup>2+</sup>]<sub>i</sub>) probably due to D-inositol-1,4,5-trisphosphate (InsP<sub>3</sub>) formation after hydrolysis of phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5P<sub>2</sub>) [2–5]. InsP<sub>3</sub> serves as a general second messenger by increasing [Ca<sup>2+</sup>]<sub>i</sub> through release from intracellular stores [6], and is considered responsible for the initial TRH secretory response (phase I) which lasts less than 1 min. After phase I, the rate of prolactin secretion is reduced, but maintained at about 50 per cent of maximum rate for several min (phase II) [7–11]. Direct measurements of [Ca<sup>2+</sup>]<sub>i</sub> using the Quin-2 method have demonstrated a similar biphasic pattern paralleling the two phases of hormone release [12, 13]. The rapid elevation of InsP<sub>3</sub> quickly subsides and can therefore not explain the sustained elevation and second rise of [Ca<sup>2+</sup>]<sub>i</sub> after TRH treatment [2, 3, 5]. During the secretory phase I, Ca<sup>2+</sup>-activated K<sup>+</sup>-channels are opened due to elevation of [Ca<sup>2+</sup>]<sub>i</sub> causing membrane hyper-

polarization, increased resistance, and suppressed firing of partly Ca<sup>2+</sup>-dependent action potentials [14, 15]. The spontaneous firing activity is regained after about 1 min of TRH exposure corresponding to the secretory phase II [16–18]. During this phase, an entry of extracellular Ca<sup>2+</sup> occurs, and this is a prerequisite for full expression of the TRH action [12].

The other product of PtdIns-4,5P<sub>2</sub> hydrolysis is 1,2-diacylglycerol (DG), which is the assumed endogenous activator of protein kinase C. Different phorbol esters, such as TPA, affect cellular processes by mimicking the effect of DG on protein kinase C [19, 20]. TPA induces a rapid and small rise in [Ca<sup>2+</sup>]<sub>i</sub> followed by an inhibitory phase with transiently lowered [Ca<sup>2+</sup>]<sub>i</sub> finally leading into a progressive and sustained elevation. This late elevation of [Ca<sup>2+</sup>]<sub>i</sub> lasts for several min in GH<sub>4</sub>C<sub>1</sub> cells. Furthermore, TPA gives rise to a phase II type of secretion [10, 21]. Also the stimulation of adenylate cyclase activity in GH<sub>4</sub>C<sub>1</sub> cells by vasoactive intestinal polypeptide (VIP) elicits a phase II type of prolactin secretion and elevates [Ca<sup>2+</sup>]<sub>i</sub> with a time-course corresponding to their secretory responses [22, 23]. In the present work on GH<sub>4</sub>C<sub>1</sub> cells, we show that both TRH and TPA stimulate the particulate bound cyclase, but that their molecular actions are different. Moreover, their effects on prolactin secretion and production are additive. This study opens the possibility that

<sup>†</sup> To whom correspondence should be addressed at: Institute for Surgical Research, The National Hospital, 0027 Oslo 1, Norway.

cAMP may be a mediator of the TRH induced phase II secretion and also plays a role in the action of TPA.

## MATERIALS AND METHODS

**Materials.** Ham's F-10 medium, horse serum, calf serum and amphotericin B were purchased from Flow Laboratory (Ervine, U.K.). Penicillin and streptomycin were from Gibco, Europe (Glasgow, U.K.). The phorbol ester (12-O-tetradecanoyl phorbol 13-acetate (TPA)) was from Sigma Chemical Company (St Louis, MO) and TRH was purchased from F. Hoffman La-Roche AG (Basle, Switzerland). Creatine phosphate and creatine kinase were obtained from Calbiochem AG (Basle, Switzerland). Myokinase, polymyxin B, ATP, cAMP and GTP were purchased from Sigma (U.S.A.). Gpp(NH)p (guanyl 5'-yl-imidodiphosphate) was obtained from Boehringer Mannheim (Germany). [ $\alpha$ - $^{32}$ P]-ATP (20–40 Ci/mmol) and [ $^3$ H]-cAMP (25 Ci/mmol) were purchased from Amersham Co. (U.K.). Bordella pertussis toxin was obtained from List Biochemical Laboratories (U.S.A.). All chemicals were of analytic grade.

**Cell culture experiments.** The GH $_4$ C $_1$  cell strain was grown in plastic tissue culture dishes, containing serum supplemented medium at 37° in a humidified atmosphere of 95% O $_2$  and 5% CO $_2$  as described previously [19]. Penicillin (50 IU/ml), streptomycin (50  $\mu$ g/ml) and amphotericin B (2.5  $\mu$ g/ml) were all added to the culture medium, which was changed every 2–3 days and always 24 hr before the experiment took place. At the time of the experiment, the monolayer cultures received new medium containing the additions as indicated for each experiment, and medium collected at the time intervals given for hormone measurements. Prolactin was measured in the medium as previously described and related to mg cell protein per dish [24].

**Adenylyl cyclase assay.** In brief, the enzyme assay was carried out in a final volume of 50  $\mu$ l and 1 mM ATP (including  $2.5 \times 10^6$  cpm/tube of [ $\alpha$ - $^{32}$ P]-ATP), 40  $\mu$ M GTP, 1 mM cAMP (with 7800 cpm/tube of [ $^3$ H]-cAMP), 1.4 mM EDTA, 0.1 mM EGTA, 2.8 mM Mg $^{2+}$ , 0.10 mM Ca $^{2+}$  and 25 mM Tris-HCl (pH 7.4) together with a regenerating system for ATP consisting of 20 mM creatine phosphate, 0.2 mg/ml of creatine kinase and 0.02 mg/ml of myokinase [25]. TRH, TPA, Gpp(NH)p (guanyl 5'-yl imidodiphosphate) or forskolin was added just prior to the incubation, which was carried out at 35° for 20 min. The reactions were stopped with 0.1 ml of a "stopping solution" containing 10 mM cAMP, 40 mM ATP and 1% sodium dodecyl sulphate followed by mixing and immediate cooling to 0°. The [ $^{32}$ P]-cAMP formed and the [ $^3$ H]-cAMP added to monitor recovery were isolated using combined Dowex and alumina oxide chromatography. The overall recovery was 65–85 per cent and the reaction blanks were 3–6 cpm per  $1 \times 10^6$  cpm of labelled ATP added. The final imidazole eluates were collected in scintillation vials containing 5 ml of Instagel (Packard) and radioactivity counted for 10 min in a liquid scintillation counter [25].

The results are given as pmoles cAMP produced




Fig. 1. The effects of TPA ( $10^{-8}$  M and  $10^{-6}$  M) and TRH ( $10^{-6}$  M) separately and in combination on prolactin secretion from monolayer cultures of GH $_4$ C $_1$  cells. The cells were treated for the indicated time periods and the first sampling period was after 30 sec. TRH at  $10^{-6}$  M and TPA at  $10^{-6}$  M elicited maximal secretory response, while TPA at  $10^{-8}$  M gave 50% stimulation [1, 10]. The secretory effects of both high and low concentration of TPA were enhanced by the concomitant addition of TRH. The effect of 4 $\alpha$ -phorbol 12,13-didecanoate (4 $\alpha$ -PDD) was not different from controls (zero value). The data are shown as mean values  $\pm$  SD from three different experiments (N = 9) where basal secretion at each point has been subtracted.

per mg membrane protein per min and shown as mean values  $\pm$  SD of triplicate determinations. All experiments were carried out twice (N = 6).

The effects of 4 $\alpha$ -PDD were similar to basal activity (data not shown).

**Statistical calculations.** The results are given as mean values and statistical significance assessed by the Wilcoxon non-parametric, two-sample test.

## RESULTS

### Effects of TRH and TPA on prolactin secretion and production

Monolayer cultures of GH $_4$ C $_1$  cells received TPA ( $10^{-8}$  M and  $10^{-6}$  M) and TRH ( $10^{-6}$  M) alone or in combination. The first medium sample was collected after 0.5 min and the accumulation of prolactin during 20 min was followed and expressed as the difference between controls and treated cultures. The two concentrations of TPA were chosen since they gave half maximal and maximal effects, respectively [10, 21]. Using this experimental protocol the amount of prolactin released reflects the TRH induced phase II secretion, which TPA mimicks closely [10] (Fig. 1). When prolactin secretion was maximally stimulated by TRH ( $10^{-6}$  M), both concentrations of TPA enhanced the release in an additive manner (Fig. 1, inset).

Table 1 shows experiments using TRH and TPA in concentrations yielding maximal effects on prolactin production [20] during incubation periods of 24 hr and 72 hr, respectively. In monolayer cultures containing the same amount of cells, TRH and TPA stimulated hormone production confirming previous results [1, 20], and the combined treatment again resulted in additive effects. After cessation of treat-

Table 1. Effects of TRH and TPA on prolactin production in GH<sub>4</sub>C<sub>1</sub> pituitary cells

Treatment groups	Prolactin production 24 hr	( $\mu\text{g/ml} \cdot 24 \text{ hr}$ ) 72 hr
Control	7.0 $\pm$ 0.5	8.2 $\pm$ 0.6
TRH( $10^{-6}$ M)	15.3 $\pm$ 1.3*	18.5 $\pm$ 1.8*
TPA( $10^{-6}$ M)	18.8 $\pm$ 1.9*	14.3 $\pm$ 1.1*
TPA( $10^{-6}$ M) + TRH( $10^{-6}$ M)	24.2 $\pm$ 1.1*†	33.6 $\pm$ 0.9*†

Monolayer cultures of GH<sub>4</sub>C<sub>1</sub> cells in Ham's F-10 medium supplemented with 12 per cent serum received TRH and TPA as indicated for 24 and 72 hr. The medium was collected and prolactin measured radioimmunologically as described previously [24]. The production of prolactin, which is not degraded intracellularly or in the medium [37], was relatively constant during each 24-hr collection period. The results are shown as mean values and SD of triplicates from one experiment which was repeated twice (N = 6). Cellular protein concentration per dish was similar in the different groups (179  $\mu\text{g} \pm 15.1$  (mean  $\pm$  S.E.)). The combined action of TRH and TPA on prolactin production were significantly over and above the effects observed when only one of the substances was used.

\* P < 0.01, treated groups vs controls.

† P < 0.01, combined treatment vs TRH or TPA treatment alone.

ment, there was a gradual and similar return to control values (data not shown).

Effects of TRH and TPA on particulate bound adenylate cyclase

There are indications that partly purified protein kinase C prevents inhibition of human platelet adenylate cyclase by epinephrine via inactivation of the G<sub>i</sub>-component [26]. The GH<sub>4</sub>C<sub>1</sub> cell has a hormone sensitive adenylate cyclase which is activated about 2-fold by TRH [25]. In the presence of a standard incubation mixture (low free [Mg<sup>2+</sup>]), TRH and TPA in concentrations known to give maximum activation show a very similar time course and magnitude of cyclase activation (Fig. 2). In combination, the effects of the two substances on the cyclase were additive. In comparison, TPA is unable to change the rate of adenylate cyclase activation by the GTP analogue Gpp(NH)p and forskolin that act on G<sub>s</sub> and on the catalytic site, respectively (Fig. 2,

inset). Also, diacyl glycerol (e.g. OAG), an assumed activator of protein kinase C, is able to stimulate the cyclase (Table 2). The cyclase activations by TRH and TPA are similar with regard to GTP-dependency.

The following results suggest that G<sub>i</sub> is inactivated by TPA: addition of polymyxin B (50 U/ml–100 U/ml), an inhibitor of protein kinase C [27], to the enzyme assay did not affect the basal activity of the cyclase, but already 50 U/ml abolished TPA activation (Table 3). However, the TRH-induced adenylate cyclase activation was only reduced about 11 per cent by the maximal concentration used. Also, adenylate cyclase activation by vasoactive intestinal polypeptide (VIP) was only reduced 14 per cent by polymyxin B when used in the maximal concentration. A further indication that the effect of TPA represented inactivation of the G<sub>i</sub>-component of the GH<sub>4</sub>C<sub>1</sub> cell cyclase was obtained by the TPA-induced blockade of the somatostatin (ST) effect. ST inhibits the cyclase through G<sub>i</sub> activation (Table 4). Similar results were also obtained when measuring total cAMP accumulation in intact cells and PRL release (data not shown). When GH<sub>4</sub>C<sub>1</sub> cells were pretreated with vanadate, causing a preferential




Fig. 2. The effects of TPA ( $10^{-6}$  M) alone and in combination with TRH ( $10^{-6}$  M), Gpp(NH)p ( $10^{-5}$  M) and forskolin ( $10^{-5}$  M) on the particulate bound adenylate cyclase in GH<sub>4</sub>C<sub>1</sub> cells.

Table 2. The effects of 1-oleyl, 2-acetyl-glycerol (OAG) on the GH<sub>4</sub>C<sub>1</sub> cell adenylate cyclase

Group	N	Formation of cAMP (pmoles/mg protein min)
Control	6	4.9 $\pm$ 0.1
OAG ( $10^{-7}$ M)	6	*5.6 $\pm$ 0.1
( $10^{-6}$ M)	6	†7.8 $\pm$ 0.2

In the experiments testing the effect of OAG, phosphatidyl serine was not present in the incubation mixture which was otherwise as described in Materials and Methods using free [Mg<sup>2+</sup>] of 0.4 mM and free [Ca<sup>2+</sup>] of 0.1 mM. The results are shown as mean values  $\pm$  SD of two separate experiments.

\* P < 0.05.

† P < 0.01.

Table 3. The effect of polymyxin B on TRH- and TPA-stimulated adenylate cyclase in prolactin producing rat pituitary GH<sub>4</sub>C<sub>1</sub> cells

Activating agent	Formation of cAMP (pmoles/mg protein · min)			
	0	Polymyxin B concentration (U/ml)		1000
		50	100	
Control	5.1 ± 0.3	5.4 ± 0.5	5.7 ± 0.4	5.6 ± 0.2
TRH (10 <sup>-6</sup> M)	9.6 ± 0.6*	9.5 ± 0.3*	9.3 ± 0.5*	8.3 ± 0.9*
TPA (10 <sup>-6</sup> M)	10.2 ± 1.0*	5.3 ± 0.4	5.0 ± 0.2	5.2 ± 0.3

Monolayer cultures were treated with polymyxin B for 20 min as described in Materials and Methods. Prewashed cells were homogenized (Ultra-Turrax) in 10 volumes of Tris-HCl/EDTA buffer (10/1 mM, pH 7.4), and particulate membrane fraction prepared [24]. Twenty  $\mu$ l aliquots were added to an incubation mixture with a final free Mg<sup>2+</sup> concentration of 0.4 mM in the absence or presence of TRH 10<sup>-6</sup> M or TPA 10<sup>-6</sup> M. The results are given as mean  $\pm$  SD of triplicate determinations and expressed as pmoles cAMP produced per mg membrane protein per minute of incubation. The experiment was repeated three times with similar results (N = 9). Asterisks indicate significant differences (P < 0.01) to zero controls.

inhibition of phosphatase activity [28], the differential TRH-sensitive cyclase activity was unaltered while TPA-stimulation was obliterated (Table 5). Thus, TPA activates the cyclase in a way different from that of TRH. Interestingly, vanadate pretreatment of the cells stimulated the cyclase activity in a dose dependent manner, but the absolute effect contributed by TRH remained almost constant (Table 5). Whether the activation of basal enzyme activity by vanadate is only due to an altered state of G<sub>i</sub> phosphorylation, is not known. However, an altered state of phosphorylation appears to be involved in the action of TPA on G<sub>i</sub>.

To further examine the molecular mechanisms by which TRH and TPA activates the GH<sub>4</sub>C<sub>1</sub> cell cyclase, experiments with cholera toxin and pertussis toxin that ADP-ribosylate G<sub>s</sub> and G<sub>i</sub> proteins of the adenylate cyclase complex, respectively, were performed. When membranes were pre-incubated with activated cholera toxin (10  $\mu$ g/ml), a 20-fold increase in basal enzyme activity was demonstrated, and TRH and TPA were unable to further sustain the response (Table 6). Pretreatment of whole cells with pertussis toxin (10  $\mu$ g/ml) increased basal enzyme activity 2.3-fold with full preservation of the TRH-sensitive cyclase, while the effect of TPA was obliterated (Table 6). These experiments further strengthened the suggestion that the TPA-dependent cyclase activation is mediated via G<sub>i</sub>.

DISCUSSION

The phase II of prolactin secretion induced by TRH is mimicked by both TPA and vasoactive intestinal polypeptide (VIP) [10, 23, 29], and all three secretagogues elevate intracellular [Ca<sup>2+</sup>]<sub>i</sub> [10, 22]. This study shows that both TRH and TPA activate the adenylate cyclase system, and that there exists an interconnection between this system and protein kinase C activation via G<sub>i</sub>. The mechanism by which the cAMP system raises [Ca<sup>2+</sup>]<sub>i</sub> is unknown, but both signal systems appear to be involved in prolactin secretion and production.

Phase II secretion in the action of TRH is dependent upon entrance of extracellular Ca<sup>2+</sup> which is probably taken up via voltage dependent Ca<sup>2+</sup>-channels during the generation of action potentials [30, 31]. Albert and Tashjian [21] have shown that the slow and sustained elevation of [Ca<sup>2+</sup>]<sub>i</sub> after TPA treatment in GH<sub>4</sub>C<sub>1</sub> cells is dependent on extracellular [Ca<sup>2+</sup>]<sub>o</sub>, and has a time course corresponding to stimulation of secretion. However, TPA regulates [Ca<sup>2+</sup>]<sub>i</sub> in a biphasic manner which may be dependent on pre-existing [Ca<sup>2+</sup>]<sub>i</sub> and whose molecular involvement and functional significance is not yet understood [21, 32]. Although there is a time-course resemblance of the effects of TPA with TRH on phase II secretion and prolactin synthesis, their effects are additive and their detailed molecular

Table 4. Inactivation of the TPA induced adenylate cyclase by somatostatin (ST)

Group	N	Formation of cAMP (pmoles/mg protein min)
Control	6	4.8 ± 0.1
TPA (10 <sup>-6</sup> M)	6	*9.6 ± 0.3
ST (10 <sup>-5</sup> M)	6	*3.0 ± 0.2
ST (10 <sup>-5</sup> M) + TPA (10 <sup>-6</sup> M)	6	5.2 ± 0.2

The enzyme was measured as described in Materials and Methods using free [Mg<sup>2+</sup>] and [Ca<sup>2+</sup>] of 0.4 mM and 0.1 mM, respectively. The results are shown as mean values  $\pm$  SD of two separate experiments.

\* P < 0.05.

Table 5. The effects of TRH and TPA on particulate bound adenylate cyclase activation in GH<sub>4</sub>C<sub>1</sub> cells pretreated with sodium vanadate

Treatment group	Formation of cAMP (pmoles/mg protein · min)		
	0	Sodium vanadate (μM) 20	40
Control	4.6 ± 0.3	6.2 ± 0.1	7.1 ± 0.4
TRH (10 <sup>-6</sup> M)	8.2 ± 0.6*	10.0 ± 1.1*	11.1 ± 0.5*
TPA (10 <sup>-6</sup> M)	8.6 ± 0.1*	6.8 ± 0.3	7.0 ± 0.6

Monolayer cultures were treated with sodium vanadate for 19 hr before harvest and preparation of the particulate membrane fraction [25]. The cyclase assay was performed with washed subcellular fractions in the absence of added vanadate as summarized in Materials and Methods. The results are shown as mean values ± SD of triplicates, and the experiment was repeated three times. Asterisks indicate results significantly ( $P < 0.01$ ) different from control ( $N = 9$ ).

Table 6. The influence of cholera toxin and pertussis toxin on basal, TRH- and TPA-activated adenylate cyclase of rat pituitary GH<sub>4</sub>C<sub>1</sub> cells

Pretreatment groups	Basal	Treatment groups TRH	TPA
Control	4.9 ± 0.1	8.3 ± 0.5*	8.9 ± 1.0*
Cholera toxin	†101 ± 8.3	†103 ± 9.2	108 ± 9.6
Pertussis toxin	†11.5 ± 1.3	†19.6 ± 2.1	10.6 ± 0.7

The data represent formation of cAMP (pmoles/mg protein · min) in different groups

Membranes (pre-incubated with activated cholera toxin, 10 μg/ml) or whole cells (pretreated with pertussis toxin, 10 μg/l) were assayed for AC activity in the presence of 0.4 mM free Mg<sup>2+</sup>, 1 mM ATP, 40 μM GTP and either TRH (10<sup>-6</sup> M) or TPA (10<sup>-6</sup> M). All values are expressed as means with SD of triplicate determinations. The experiment was repeated twice ( $N = 6$ ).

\* Indicates  $P < 0.05$  for horizontal (within-group) comparisons with basal activity and † depicts  $P < 0.05$  for vertical (between-group) comparisons with corresponding controls.

actions different as regards adenylate cyclase activation and [Ca<sup>2+</sup>]<sub>i</sub> regulation [21, 33].

The detailed delineation of how the different TRH-evoked second messenger signals may operate in these cells to alter hormone secretion as well as gene expression, has proved intricate. However, this work shows that there may be an important cooperation between protein kinase C and adenylate cyclase. This possible interaction may prove important for mediating secretory phase II and stimulated hormone production in the TRH action, and it also makes possible feed-back mechanisms aimed to potentiate or to terminate the action of TRH on sites distal to ligand-receptor binding. An interaction between phorbol esters and cAMP in regulating ion transport has been described also for other biological systems. Phorbol esters inhibit K<sup>+</sup>-currents evoked by cAMP in *Xenopus* oocytes [34]. Also, Baraban *et al.* [35] have shown that phorbol esters blocked the Ca<sup>2+</sup>-dependent K<sup>+</sup>-conductance in hippocampal pyramidal neurons, an effect similar to that previously observed following activation of cAMP dependent protein kinase [36]. Hence, this study also offers a possible explanation for these two apparently discrepant observations.

TPA has recently been shown to depolarize GH cells leading to increased firing of action potentials [10]. The present results open the possibility that TPA-induced inhibition of K<sup>+</sup>-conductance [10] may occur via its effect on G<sub>i</sub>.

**Acknowledgements**—We thank The Norwegian Cancer Society, Anders Jahre's Foundation for promotion of Science, Norwegian Research Council for Science and the Humanities (NAVF), Oslo and Nordisk Insulinfond, Gentofte, Denmark, for financial support. J.G. is in receipt of a senior research grant from NAVF.

## REFERENCES

1. Osborne R and Tashjian AH Jr, Modulation of peptide binding to specific receptors on rat pituitary cells by tumor-promoting phorbol esters: decreased binding of thyrotropin-releasing hormone and somatostatin as well as epidermal growth factor. *Cancer Res* 42: 4375–4381, 1982.
2. Rebecchi MJ and Gerschengorn MC, Thyroliberin stimulates rapid hydrolysis of phosphatidylinositol 4,5-bisphosphate by a phosphodiesterase in rat mammotropic pituitary cells. *Biochem J* 216: 287–294, 1983.
3. Martin TFJ, Thyrotropin-releasing hormone rapidly activates the phosphodiester hydrolysis of polyphos-

- phoinositides in GH<sub>3</sub> pituitary cells: evidence for the role of a polyphosphoinositide-specific phospholipase C in hormone action. *J Biol Chem* **258**: 14816–14822, 1983.
4. Macphee CH and Drummond AH, Thyrotropin-releasing hormone stimulates rapid breakdown of phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 4-phosphate in GH<sub>3</sub> pituitary tumor cells. *Mol Pharmacol* **25**: 193–200, 1984.
5. Drummond AH, Bushfield M and Macphee CH, Thyrotropin-releasing hormone-stimulated [<sup>3</sup>H] inositol metabolism in GH<sub>3</sub> pituitary tumor cells. *Mol Pharmacol* **25**: 201–208, 1984.
6. Berridge MJ and Irvine RF, Inositol trisphosphate, a novel second messenger in cellular signal transduction. *Nature (Lond)* **312**: 315–321, 1984.
7. Martin TFI and Kowalchuk JA, Evidence for the role of calcium and diacylglycerol as dual second messengers in thyrotropin-releasing hormone action: involvement of diacylglycerol. *Endocrinology* **115**: 1517–1526, 1984.
8. Martin TFI and Kowalchuk JA, Evidence for the role of calcium and diacylglycerol as dual second messengers in thyrotropin-releasing hormone action: involvement of Ca<sup>2+</sup>. *Endocrinology* **115**: 1527–1536, 1984b.
9. Gershengorn M, Geras E, Purrello VS and Rebecchi MJ, Inositol trisphosphate mediates thyrotropin-releasing hormone mobilization of non mitochondrial calcium in rat mammotropic pituitary cells. *J Biol Chem* **259**: 10675–10681, 1984.
10. Østberg BC, Sand O, Bjørø T and Haug E, The phorbol ester TPA induces hormone release and electrical activity in clonal rat pituitary cells. *Acta Physiol Scand* **126**: 517–524, 1986.
11. Tsien RY, Pozzan T and Rink TJ, Calcium homeostasis in intact lymphocytes: cytoplasmic free calcium monitored with a new, intracellularly trapped fluorescent indicator. *J Cell Biol* **94**: 325–334, 1982.
12. Albert PR and Tashjian AH, Thyrotropin-releasing hormone-induced spike and plateau in cytosolic free calcium concentration in pituitary cells: relation to prolactin release. *J Biol Chem* **259**: 5827–5832, 1984.
13. Gershengorn MC and Thaw C, Thyrotropin-releasing hormone (TRH) stimulates biphasic elevation of cytoplasmic free calcium in GH<sub>3</sub> cells. Further evidence that TRH mobilizes cellular and extracellular Ca<sup>2+</sup>. *Endocrinology* **116**: 591–596, 1985.
14. Dubinsky JM and Oxford SG, Dual modulation of K channels by thyrotropin-releasing hormone in clonal pituitary cells. *Proc Natl Acad Sci USA* **82**: 4282–4286, 1985.
15. Ozawa S, TRH-induced membrane hyperpolarization in rat clonal anterior pituitary cells. *Am J Physiol* **248**: E64–E69, 1985.
16. Dufy B, Vincent JD, Fleury H, Du Pasquier P, Gourdji D and Tixier-Vidal A, Membrane effects of thyrotropin-releasing hormone and estrogen shown by intracellular recording from pituitary cells. *Science* **204**: 509–511, 1979.
17. Ozawa S and Kimura N, Membrane potential changes caused by thyrotropin-releasing hormone in the clonal GH<sub>3</sub> cell and their relationship to secretion of pituitary hormone. *Proc Natl Acad Sci USA* **76**: 6017–6020, 1979.
18. Ozawa S, Biphasic effect of thyrotropin-releasing hormone on membrane K<sup>+</sup> permeability in rat clonal pituitary cells. *Brain Res* **209**: 240–244, 1981.
19. Gautvik KM, Iversen J-G and Sand O, On the role of extracellular Ca<sup>2+</sup> for prolactin release and adenosine 3':5' monophosphate formation induced by thyroliberin in cultured rat pituitary cells. *Life Sci* **26**: 995–1005, 1980.
20. Ashendel CI, The phorbol ester receptor: a phospholipid-regulated protein kinase. *Biochim Biophys Acta* **822**: 219–242, 1985.
21. Albert PR and Tashjian AH Jr, Dual actions of phorbol esters on cytosolic free calcium concentrations and re-constitution with ionomycin of acute thyrotropin-releasing hormone responses. *J Biol Chem* **260**: 8746–8759, 1985.
22. Bjørø T, Østberg BC, Sand O, Gordeladze J, Iversen J-G, Torjesen PA, Gautvik KM and Haug E, Vasoactive intestinal peptide and peptide with N-terminal histidine and C-terminal isoleucine increase prolactin secretion in cultured rat pituitary cells (GH<sub>3</sub>C<sub>1</sub>) via a cAMP-dependent mechanism which involves transient elevation of intracellular Ca<sup>2+</sup>. *Mol Cell Endocr* **49**: 119–128, 1987.
23. Gordeladze JO, Bjørø T, Østberg BC, Torjesen PA, Haug E and Gautvik KM, Vasoactive intestinal polypeptide (VIP) and thyroliberin (TRH) activate adenylate cyclase (AC) in prolactin (PRL) producing pituitary tumour (GH<sub>3</sub>C<sub>1</sub>) cells via different molecular mechanisms. *Mol Cell Endocr*, in press, 1988.
24. Gautvik KM, Walaas E and Walaas O, Effect of thyroliberin on the concentration of adenosine 3':5'-phosphate-dependent protein kinase in prolactin-producing cells in culture. *Biochem J* **162**: 379–386, 1977.
25. Gautvik KM, Gordeladze JO, Jahnsen T, Haug E, Hansson V and Lystad E, Thyroliberin receptor binding and adenyl cyclase activation in cultured prolactin producing rat pituitary tumor cells (GH cells). *J Biol Chem* **258**: 10304–10311, 1983.
26. Watanabe Y, Horn F, Bauer S and Jakobs KH, Protein kinase C interferes with N<sub>i</sub>-mediated inhibition of human platelet adenylate cyclase. *FEBS Lett* **192**: 23–27, 1985.
27. Kuo JF, Schatzman RC, Scott Turner R and Mazzei GJ, Phospholipid-sensitive Ca<sup>2+</sup>-dependent protein kinase: a major protein phosphorylation system. *Mol Cell Endocr* **35**: 65–73, 1984.
28. Klarlund JK, Transformation of cells by an inhibitor of phosphatases acting on phosphotyrosine in proteins. *Cell* **41**: 707–717, 1985.
29. Bjørø T, Haug E, Sand O and Gautvik KM, Vasoactive intestinal peptide causes a calcium-dependent stimulation of prolactin secretion in GH<sub>3</sub>C<sub>1</sub> cells. *Mol Cell Endocrinol* **37**: 41–50, 1984.
30. Kidokoro Y, Spontaneous Ca action potentials in a clonal pituitary cell line and their relationship to prolactin secretion. *Nature (Lond)* **258**: 741–742, 1975.
31. Sand O, Haug E and Gautvik KM, Effects of thyroliberin and 4-aminopyridine on action potentials and prolactin release and synthesis in rat pituitary cells in culture. *Acta Physiol Scand* **108**: 247–257, 1980.
32. Drummond AH, Bidirectional control of cytosolic free calcium by thyrotropin-releasing hormone in pituitary cells. *Nature (Lond)* **315**: 752–755, 1985.
33. Delbecke D, Kojima I, Dannies PS and Rasmussen H, Synergistic stimulation of prolactin release by phorbol ester, A23187 and forskolin. *Biochem Biophys Res Commun* **123**: 735–741, 1984.
34. Dascal N, Lotan I, Gilbo B, Lester HA and Lass Y, Acetylcholine and phorbol esters inhibit potassium currents evoked by adenosine and cAMP in *Xenopus* oocytes. *Proc Natl Acad Sci USA* **82**: 6001–6005, 1985.
35. Baraban JM, Snyder S and Alger B, Protein kinase C regulates ionic conductance in hippocampal pyramidal neurons: electrophysiological effects of phorbol esters. *Proc Natl Acad Sci USA* **82**: 2538–2542, 1985.
36. Madison DV and Nicoll RA, Noradrenaline blocks accommodation of pyramidal cell discharge in the hippocampus. *Nature (Lond)* **299**: 636–638, 1982.
37. Haug E, Tjernshaugen H and Gautvik KM, Variations in prolactin and growth hormone production during cellular growth in clonal strains of rat pituitary cells. *J Cell Physiol* **91**: 15–30, 1977.